MS67 exhibited potent growth suppression of AML cells from deidentified patients in vitro and displayed efficacy in an MLL-AF9+ AML PDX-xenograft model, leading to prolonged survival rates without any significant loss of body weight. This evidence concerns the gene MLLT3 and acute myeloid leukemia.